Saran Lotfollahzadeh
Postdoctoral Associate NRSA , Preventive Medicine
Biography
I am a physician-scientist. I underwent medical school training and embarked on an integrated five-year general and vascular surgery residency program followed by a clinical fellowship in Pediatric and Vascular Surgery focusing on cardiovascular complications and hemodialysis access in patients with end-stage kidney disease. In doing so, I developed a deep appreciation of the impact of vascular morbidities on overall disease burden. During my clinical training, I performed epidemiological research in an interdisciplinary setup as a country lead with a group in King’s College, UK. However, I was not exposed to the power of translational research. Upon joining the lab of Dr. Chitalia at the Boston University School of Medicine, I was exposed to how to bring clinically relevant problems to testing them bench and dissect mechanistically. With my clinical experience in vascular medicine, oncosurgery, and research experience in thrombosis, I was granted an AHA SFRN fellowship on cardio-oncology. I have developed various animal models, such as different models of femoral artery ligation for hind limb ischemia and inferior vena cava ligation assays in mice as a model of deep vein thrombosis. My passion is to understand molecular pathobiology driving such fundamental processes and amalgamate the clinical experience with translational science focusing on cardiometabolic risk factors.
Websites
Publications
- Published on 1/30/2025
Subramaniam S, Napoleon MA, Lotfollahzadeh S, Kamal MH, Kurniawan H, Elsadawi M, Kenney D, Douam F, Bosmann M, Whelan S, Cabral H, Burks EJ, Zhao G, Kolachalama V, Ravid K, Chitalia V. Tryptophan metabolism reprogramming contributes to the prothrombotic milieu in mice and humans infected with SARS-CoV-2. bioRxiv. 2025 Jan 30. PMID: 39896681.
Read at: PubMed - Published on 12/3/2024
Dulberger KN, La J, Li A, Lotfollahzadeh S, Jose A, Do NV, Brophy MT, Gaziano JM, Ravid K, Chitalia VC, Fillmore NR. External validation of a novel cancer-associated venous thromboembolism risk assessment score in a safety-net hospital. Res Pract Thromb Haemost. 2025 Jan; 9(1):102650. PMID: 39839661.
Read at: PubMed - Published on 9/1/2024
Lotfollahzadeh S, Vazirani A, Sellinger IE, Clovie J, Hoekstra I, Patel A, Malloum AB, Yin W, Paul H, Yadati P, Siracus J, Malikova M, Pernar LI, Francis J, Stern L, Chitalia VC. Aryl Hydrocarbon Receptor Pathway Augments Peritoneal Fibrosis in a Murine CKD Model Exposed to Peritoneal Dialysate. Kidney360. 2024 Sep 01; 5(9):1238-1250. PMID: 39235862.
Read at: PubMed - Published on 6/26/2024
Zhu M, Farber A, King E, Alonso A, Kobzeva-Herzog A, Cooper J, Lotfollahzadeh S, Chitalia VC, Siracuse JJ. Early Kidney Transplantation or Conversion to Peritoneal Dialysis after First-Time Arteriovenous Access Creation. Ann Vasc Surg. 2024 Nov; 108:57-64. PMID: 38942372.
Read at: PubMed - Published on 5/29/2024
Bathla T, Lotfollahzadeh S, Quisel M, Mehta M, Malikova M, Chitalia VC. End Organ Affection in Sickle Cell Disease. Cells. 2024 May 29; 13(11). PMID: 38891066.
Read at: PubMed - Published on 5/22/2024
Lotfollahzadeh S, Jose A, Zarnaab Shafiq E, El Sherif N, Smith M, Han J, Seta F, Chitalia V. Two methods of isolation of rat aortic smooth muscle cells with high yield. Biol Methods Protoc. 2024; 9(1):bpae038. PMID: 39006461.
Read at: PubMed - Published on 4/16/2024
Zhang M, Lotfollahzadeh S, Elzinad N, Yang X, Elsadawi M, Gower AC, Belghasem M, Shazly T, Kolachalama VB, Chitalia VC. Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment. Vasc Med. 2024 Aug; 29(4):369-380. PMID: 38623630.
Read at: PubMed - Published on 1/5/2024
Lotfollahzadeh S, Yang X, Wu Wong DJ, Han J, Seta F, Ganguli S, Jose A, Ravid K, Chitalia VC. Venous Thrombosis Assay in a Mouse Model of Cancer. J Vis Exp. 2024 Jan 05; (203). PMID: 38251710.
Read at: PubMed - Published on 11/23/2023
Rahimi N, White MR, Amraei R, Lotfollahzadeh S, Xia C, Michalak M, Costello CE, Mühlberger E. Calreticulin Regulates SARS-CoV-2 Spike Protein Turnover and Modulates SARS-CoV-2 Infectivity. Cells. 2023 Nov 23; 12(23). PMID: 38067122.
Read at: PubMed - Published on 9/5/2023
Belghasem M, Yin W, Lotfollahzadeh S, Yang X, Meyer RD, Napoleon MA, Sellinger IE, Vazirani A, Metrikova E, Jose A, Zhebrun A, Whelan SA, Lee N, Rahimi N, Chitalia VC. Tryptophan Metabolites Target Transmembrane and Immunoglobulin Domain-Containing 1 Signaling to Augment Renal Tubular Injury. Am J Pathol. 2023 Oct; 193(10):1501-1516. PMID: 37676196.
Read at: PubMed
View 24 more publications: View full profile at BUMC